Novartis Acquires Chinese Vaccine Company - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis Acquires Chinese Vaccine Company


ePT--the Electronic Newsletter of Pharmaceutical Technology

Novartis acquired a majority stake in Zhejiang Tianyuan Bio-Pharmaceutical, one of the largest privately held vaccine companies in China. The acquisition gives Novartis an expanded presence in the Chinese vaccine market and will facilitate the introduction of Novartis's vaccines into the country.

"This agreement combines the strength of our vaccines research and development strategy and pipeline with Tianyuan's deep knowledge of the vaccines market in China," said Andrin Oswald, Head of Novartis Vaccines and Diagnostics, in a statement.

According to the statement, Novartis will collaborate with Tianyuan to strengthen its vaccine portfolio and pipeline, as well as align production processes and quality standards. Novartis also added that it plans to explore new vaccine developments to address unmet medical needs in China.

"We have already identified several joint development programs that could be implemented in China over the next 10 years, with the potential of launching key products responding to unmet medical needs in the mid-term," said Ding Xiaohang, Founder, Chairman and CEO of Tianyuan, in the statement.

In related news, Novartis will eliminate more than 500 positions at its Horsham, United Kingdom site. The full story is available at BBC news.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here